$1.20 4.4%
ADIL Stock Price vs. AI Score
Data gathered: December 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Adial Pharmaceuticals (ADIL)

Analysis generated April 23, 2024. Powered by Chat GPT.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders. The flagship product candidate of Adial is AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The uniqueness of this approach lies in the personalized treatment paradigm based on genetic markers. The company's mission is to provide effective treatment options for patients with addiction problems where there is a significant unmet medical need.

Read full AI stock Analysis

Stock Alerts - Adial Pharmaceuticals (ADIL)

company logo Adial Pharmaceuticals | December 5
Price is down by -6.7% in the last 24h.
company logo Adial Pharmaceuticals | December 4
Price is up by 6.3% in the last 24h.
company logo Adial Pharmaceuticals | December 3
Price is up by 8.4% in the last 24h.
company logo Adial Pharmaceuticals | December 2
Price is up by 5% in the last 24h.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.


Adial Pharmaceuticals
Price $1.20
Target Price Sign up
Volume 158,860
Market Cap $7.4M
Year Range $0.95 - $2.98
Dividend Yield 0%
Analyst Rating 0% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2401.2M-1.2M-2.2M-2.2M0.000
Q2 '2482,0001.3M-1.3M-2.5M-2.3M-0.590
Q1 '2432,0005.9M-5.9M-6.5M-1.8M-0.620
Q4 '237.5M1.5M-1.5M-1.9M-1.8M-1.350
Q3 '2301.2M-1.2M-1.4M-1.4M-1.180

Insider Transactions View All

Schuyler Kevin filed to buy 700 shares at $2.7.
October 3 '23
Newman James W. Jr. filed to buy 50,221 shares at $2.7.
January 3 '22
Newman James W. Jr. filed to buy 34,644 shares at $2.7.
January 3 '22

What is the Market Cap of Adial Pharmaceuticals?

The Market Cap of Adial Pharmaceuticals is $7.4M.

What is the current stock price of Adial Pharmaceuticals?

Currently, the price of one share of Adial Pharmaceuticals stock is $1.20.

How can I analyze the ADIL stock price chart for investment decisions?

The ADIL stock price chart above provides a comprehensive visual representation of Adial Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Adial Pharmaceuticals shares. Our platform offers an up-to-date ADIL stock price chart, along with technical data analysis and alternative data insights.

Does ADIL offer dividends to its shareholders?

As of our latest update, Adial Pharmaceuticals (ADIL) does not offer dividends to its shareholders. Investors interested in Adial Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Adial Pharmaceuticals?

Some of the similar stocks of Adial Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.